Search

Displaying results 2991 - 3000 of 10000 in total
  1. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    Mantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. … Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients remains poor and those that relapse following BTK inhibitor

  2. Drug

    Meningococcal polysaccharide vaccine group A

    go.drugbank.com/drugs/DB13889
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.

    Mixtures: MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADET, MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADET
  3. Drug

    rPSGL-Ig

    go.drugbank.com/drugs/DB06256
    Investigational

    Recombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a fusion protein of human P-selectin ligand and IgG1-Fc.

    Synonyms: rPSGL-Ig, rPSGL-1-Ig
  4. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion. … [L54903] Tradipitant has also been investigated in gastroparesis,COVID-19-induced pneumonia, and atopic dermatitis.[A275348, A275358, A275363]

    Synonyms: (2-(1-(3,5-BIS(TRIFLUOROMETHYL)BENZYL)-5-PYRIDIN-4-YL-1H-1,2,3-TRIAZOL-4-YL)PYRIDIN-3-YL)(2-CHLOROPHENYL)METHANONE, METHANONE, (2-(1-((3,5-BIS(TRIFLUOROMETHYL)PHENYL)METHYL)-5-(4-PYRIDINYL)-1H-1,2,3-TRIAZOL-4-YL)-3-PYRIDINYL)(2-CHLOROPHENYL)-Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2C19 Substrates
  5. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    the secondary solvent-front mutation _G2032R_ is 400-times lower than that of the previously approved first-generation inhibitors [crizotinib] and [entrectinib]. … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates
  6. Drug

    Fennel

    go.drugbank.com/drugs/DB15615
    Approved

    Mixtures: Digestion-Bloating-GasCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors
  7. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.

  8. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650] … [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc.

    Categories: Complement 5a Receptor Antagonist, Cytochrome P-450 Substrates
  9. Drug

    Suplatast

    go.drugbank.com/drugs/DB19138
    Investigational

    Suplatast is under investigation in clinical trial NCT05983471 (Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)).

  10. Target

    NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial

    go.drugbank.com/bio_entities/BE0000081
    TargetHumans

    Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The ...

    Polypeptides: NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial